SCHEMBL31301567

SCHEMBL31301567

O=C(O)c1ccc(Nc2nc(N3CCC(O)CC3)c3c(-c4cccc(Cl)c4)c[nH]c3n2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STK3 Q13188 9/20 0.58
▸ LRRK2 Q5S007 8/20 0.58
▸ STK4 Q13043 8/20 0.58
▸ PDE4B Q07343 4/20 0.53
▸ PDE4D Q08499 4/20 0.53
▸ MET P08581 4/20 0.48
▸ AXL P30530 4/20 0.48
▸ MERTK Q12866 4/20 0.48
▸ CDC7 O00311 1/20 0.45
▸ PLK4 O00444 1/20 0.45
▸ CHEK1 O14757 1/20 0.45
▸ AURKA O14965 1/20 0.45
▸ PDPK1 O15530 1/20 0.45
▸ JAK2 O60674 1/20 0.45
▸ ROCK2 O75116 1/20 0.45
▸ PAK4 O96013 1/20 0.45
▸ CHEK2 O96017 1/20 0.45
▸ EGFR P00533 1/20 0.45
▸ NTRK1 P04629 1/20 0.45
▸ PRKCG P05129 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31301757 0.90 LRRK2 (0.58) STK3LRRK2STK4PDE4BPDE4D
SCHEMBL31301696 0.86 STK3 (0.59) STK3LRRK2STK4METAXL
SCHEMBL31301644 0.85 STK3 (0.55) STK3LRRK2STK4METAXL
SCHEMBL31301715 0.81 LRRK2 (0.55) STK3LRRK2STK4METAXL
SCHEMBL31301590 0.75 LRRK2 (0.57) STK3LRRK2STK4METAXL
SCHEMBL31301607 0.75 LRRK2 (0.59) STK3LRRK2STK4METAXL
SCHEMBL31301784 0.75 LRRK2 (0.61) STK3LRRK2STK4METAXL
SCHEMBL31301556 0.74 LRRK2 (1.00) STK3LRRK2STK4METCDC7
SCHEMBL31301605 0.74 LRRK2 (0.55) STK3LRRK2STK4METAXL
SCHEMBL15657726 0.70 PDE4B (1.00) PDE4BPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250051337-A1 INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-02-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051337-A1 INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF STK3, STK4, STK36 STK3 1/4885LRRK2 210/4885STK4 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback